Clinical Trial Update: A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) [Phase 1]

View source ↗

Summary

Phase 1 study of escalating doses of a vaccine-based immunotherapy regimen for prostate cancer (PrCa VBIR) was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostatic Neoplasms

Drugs mentioned

• PrCa VBIR

Snippet

Sponsor: Pfizer | Conditions: Prostatic Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2023-11-02